A privately held, clinical-stage immunotherapy company developing first-in-class medicines to deliver transformational benefits for people with cancer, South San Francisco-based Tizona Therapeutics (“Tizona”) translates scientific breakthroughs into therapeutics that stimulate the immune system and counter immune suppression. Brandsymbol previously worked with MPM Capital to create Tizona’s corporate brand (verbal and visual) identity.
On July 21, 2020, Gilead Sciences (“Gilead”) announced an investment of $300 million to acquire a 49.9% equity interest in Tizona with an exclusive option to acquire the remainder of Tizona. Prior to closing the Gilead transaction, the Tizona team spun out their lead asset, TTX-030, and created a new company: Trishula Therapeutics.
Trishula was charged with demonstrating TTX-030’s clinical proof-of-concept; following that, AbbVie will assume worldwide licensing rights to TTX-030. Based on our previous work to create Tizona’s corporate brand identity, the Trishula team commissioned Brandsymbol to develop a distinct and memorable visual identity for the new company.